Welcome and Program Panel Introduction
||Cecilia Chaparro, MD, Toronto General Hospital, Toronto, ON, Canada
Monique Malouf, MD, St. Vincent’s Hospital, Sydney, Australia
Optimizing Transplant Referral for CF Patients Using Cystic Fibrosis Foundation Referral Guidelines
Carli Lehr, MD, Cleveland Clinic, Cleveland, OH, USA
Medical Strategies to Improve CF Survival to Lung Transplant
A. Whitney Brown, MD, Inova Fairfax Hospital, Falls Church, VA, USA
Unique Pre-Transplant Non-Microbiological Considerations for CF Lung Transplant Candidates
Christian Benden, MD, MBA, FCCP, Swisstransplant, Berne, Switzerland
Molecular Basis for CF Modulator Therapies: From Bench to Bedside
Michelle Murray, MD, MSc, MRCPi, Mater Misericordiae University Hospital, Dublin, Ireland
Pharmacokinetics and Therapeutic Drug Monitoring: Considerations in the Post-transplant CF Patient
Jas Parmar, PhD, FRCP, Papworth Hospital, Cambridge, UK
Moderated Q & A Segment with All Presenters
ISHLT Advanced Lung Failure and Transplantation IDN Update
Glen Westall, FRACP, PhD, The Alfred Hospital, Melbourne, Australia
Chair, Advanced Lung Failure and Transplantation Interdisciplinary Network Steering Committee
Greg Schultz, CEO, ISHLT, Addison, TX, USA
Continuing Education Information
– at the conclusion of this session, attendees will be able to:
- Discuss Optimizing Transplant Referral for CF Patients Using Cystic Fibrosis Foundation
- Discuss Medical Strategies to Improve CF Survival to Lung Transplant
- Discuss Unique Pre-Transplant Non-Microbiological Considerations for CF Lung Transplant Candidates
- Discuss Molecular Basis for CF Modulator Therapies
- Discuss Pharmacokinetic and Therapeutic Drug Monitoring
– The target audience for the December webinar session includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the management and treatment of patients with advanced heart or lung disease, basic science or clinical research related to these fields, or other specialties which cause them to become involved in the treatment of patients with advanced heart or lung disease.
Activity Designed to Change
– This activity is designed to change knowledge, competence and performance.
Patient Care and Medical Knowledge
– Current guidelines state that participants in continuing medical and allied health professional education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation or service as Chair/Planner. Disclosures will be distributed in the Learner Notification that you receive as a participant prior to the live virtual session. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.
– The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the ISHLT.
Documenting CME Credits
– The ISHLT provides CME certificates to those who have participated in an ISHLT educational activity. The ISHLT does not submit credits to regulating bodies or certifying organizations on behalf of the participants. It is the participants responsibility to submit proof of credits on his or her own behalf.
Accreditation Statement -
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement –
ISHLT designates this live virtual activity for a maximum of 1.5 AMA PRA Category 1 Credits™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and The International Society for Heart and Lung Transplantation (ISHLT). Amedco LLC is jointly accredited by the American Council for Continuing Medical Education (ACCME) the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation Statement –
Amedco LLC designates this live activity for a maximum of 1.5 contact hours for nurses.
Amedco LLC has submitted an application to the Accreditation Council for Pharmacy Education (ACPE) for continuing education credits for this activity.
Note to Pharmacists:
The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education.
Transplant Coordinators Credit
As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart and Lung Transplantation grants up to 1 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Approval Number: 221-19.